长春高新(000661) - 2018 Q3 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for the first three quarters of 2018 is expected to be between 779 million and 925 million CNY, representing a year-on-year growth of 60% to 90%[3] - The basic earnings per share are projected to be approximately 4.58 to 5.43 CNY, compared to 2.86 CNY in the same period last year[3] - The increase in net profit is primarily due to revenue growth from key pharmaceutical enterprises and an increase in revenue from real estate development projects[5] Reporting and Auditing - The performance forecast has not been audited by a registered accountant[4] - The specific data will be detailed in the company's third-quarter report for 2018[6]